<p>The present study demonstrated the design and synthesis of sulfonamide-1,2,3-triazole-acetamide derivatives <b>11a-o</b> and screening against urease in vitro and in silico. These compounds were designed based on reported potent urease inhibitors and optimized structurally based on substituents on acetamide moiety. In vitro studies showed that all the new compounds <b>11a-o</b> (IC<sub>50</sub> values = 0.12–4.53 µM) were more potent than stand inhibitor thiourea (IC<sub>50</sub> value = 23.76 µM). In this regard, the most potent compounds were N-phenylacetamide derivatives <b>11b</b>, <b>11f</b>, and <b>11 h</b> with 2-methyl, 4-methoxy, and 2-fluoro substituents, respectively. In this regard, the most potent compound <b>11b</b> was 198-folds more potent than thiourea against urease. In silico studies demonstrated that this compound with the binding energy less than thiourea attached to the urease’s active site. Druglikeness, pharmacokinetics, and toxicity of compound <b>11b</b> and thiourea were predicted by two credible online servers. These in silico studies showed that, in terms of druglikeness and pharmacokinetics, compound <b>11b</b> was almost similar to thiourea while in term of toxicity, compound <b>11b</b> was better than thiourea.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Design, synthesis, and anti-urease evaluations of new sulfonamide-1,2,3-triazole-acetamide derivatives

  • Shohreh Bakhshi Varzaneh,
  • Amir Shervin Shokouhi Asl,
  • Mohammad Hosein Sayahi,
  • Amir Mohammad Taherkhani,
  • Meysam Talebi,
  • Navid Dastyafteh,
  • Sajedeh Safapoor,
  • Mehdi Emadi,
  • Majid Alikhani,
  • Rozita Yazzaf,
  • Mohammad Halimi,
  • Massoud Amanlou,
  • Bagher Larijani,
  • Maryam Mohammadi-Khanaposhtani,
  • Mohammad Mahdavi

摘要

The present study demonstrated the design and synthesis of sulfonamide-1,2,3-triazole-acetamide derivatives 11a-o and screening against urease in vitro and in silico. These compounds were designed based on reported potent urease inhibitors and optimized structurally based on substituents on acetamide moiety. In vitro studies showed that all the new compounds 11a-o (IC50 values = 0.12–4.53 µM) were more potent than stand inhibitor thiourea (IC50 value = 23.76 µM). In this regard, the most potent compounds were N-phenylacetamide derivatives 11b, 11f, and 11 h with 2-methyl, 4-methoxy, and 2-fluoro substituents, respectively. In this regard, the most potent compound 11b was 198-folds more potent than thiourea against urease. In silico studies demonstrated that this compound with the binding energy less than thiourea attached to the urease’s active site. Druglikeness, pharmacokinetics, and toxicity of compound 11b and thiourea were predicted by two credible online servers. These in silico studies showed that, in terms of druglikeness and pharmacokinetics, compound 11b was almost similar to thiourea while in term of toxicity, compound 11b was better than thiourea.